company background image
603567 logo

Heilongjiang ZBD Pharmaceutical SHSE:603567 Stock Report

Last Price

CN¥11.77

Market Cap

CN¥11.0b

7D

-1.9%

1Y

-5.5%

Updated

18 Dec, 2024

Data

Company Financials

Heilongjiang ZBD Pharmaceutical Co., Ltd.

SHSE:603567 Stock Report

Market Cap: CN¥11.0b

603567 Stock Overview

Heilongjiang ZBD Pharmaceutical Co., Ltd. More details

603567 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

Heilongjiang ZBD Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Heilongjiang ZBD Pharmaceutical
Historical stock prices
Current Share PriceCN¥11.77
52 Week HighCN¥13.63
52 Week LowCN¥8.89
Beta0.29
1 Month Change0.77%
3 Month Change15.73%
1 Year Change-5.54%
3 Year Change-21.43%
5 Year Change2.88%
Change since IPO-30.72%

Recent News & Updates

We Like The Quality Of Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings

Nov 05
We Like The Quality Of Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings

Getting In Cheap On Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Is Unlikely

Oct 18
Getting In Cheap On Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Is Unlikely

Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly

Sep 26
Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly

Recent updates

We Like The Quality Of Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings

Nov 05
We Like The Quality Of Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings

Getting In Cheap On Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Is Unlikely

Oct 18
Getting In Cheap On Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Is Unlikely

Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly

Sep 26
Heilongjiang ZBD Pharmaceutical (SHSE:603567) Seems To Use Debt Quite Sensibly

Does Heilongjiang ZBD Pharmaceutical (SHSE:603567) Have A Healthy Balance Sheet?

May 28
Does Heilongjiang ZBD Pharmaceutical (SHSE:603567) Have A Healthy Balance Sheet?

Why Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings Are Better Than They Seem

May 06
Why Heilongjiang ZBD Pharmaceutical's (SHSE:603567) Earnings Are Better Than They Seem

Insufficient Growth At Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Hampers Share Price

Apr 17
Insufficient Growth At Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Hampers Share Price

Shareholder Returns

603567CN PharmaceuticalsCN Market
7D-1.9%-2.8%-2.6%
1Y-5.5%-3.9%9.7%

Return vs Industry: 603567 underperformed the CN Pharmaceuticals industry which returned -3.9% over the past year.

Return vs Market: 603567 underperformed the CN Market which returned 9.7% over the past year.

Price Volatility

Is 603567's price volatile compared to industry and market?
603567 volatility
603567 Average Weekly Movement6.1%
Pharmaceuticals Industry Average Movement7.4%
Market Average Movement8.7%
10% most volatile stocks in CN Market12.8%
10% least volatile stocks in CN Market5.8%

Stable Share Price: 603567 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 603567's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19962,545Jiujiang Yanwww.zbdzy.com

Heilongjiang ZBD Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese medicines in China. It offers cardiovascular and cerebrovascular, respiratory system, orthopedics, tumors, digestive system, anti-infection, mental nerve, genitourinary, and other disease fields. The company was founded in 1996 and is based in Hulin, China.

Heilongjiang ZBD Pharmaceutical Co., Ltd. Fundamentals Summary

How do Heilongjiang ZBD Pharmaceutical's earnings and revenue compare to its market cap?
603567 fundamental statistics
Market capCN¥11.03b
Earnings (TTM)CN¥653.39m
Revenue (TTM)CN¥3.12b

16.9x

P/E Ratio

3.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
603567 income statement (TTM)
RevenueCN¥3.12b
Cost of RevenueCN¥1.67b
Gross ProfitCN¥1.45b
Other ExpensesCN¥792.19m
EarningsCN¥653.39m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.70
Gross Margin46.37%
Net Profit Margin20.96%
Debt/Equity Ratio40.5%

How did 603567 perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

29%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 10:05
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Heilongjiang ZBD Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen Wen ShenAvic Securities Co., Ltd
Song YangTianfeng Securities Brokerage Co., Ltd